Minerva endocrinology最新文献

Uncomplicated diabetes and adverse in-hospital outcomes in tumor lysis syndrome: a national cohort analysis. 肿瘤溶解综合征的无并发症糖尿病和不良住院结果：一项国家队列分析。

IF 2.3

Minerva endocrinology Pub Date : 2026-09-01 Epub Date: 2026-05-12 DOI: 10.23736/S2724-6507.26.04552-5

Fiqe Khan, Aamir S Javed, Meher Ayyazuddin, Abdullah Ahmad

引用次数: 0

A review of survodutide: a new dual acting agonist. 一种新的双作用激动剂——生存肽的研究进展。

IF 2.3

Minerva endocrinology Pub Date : 2026-09-01 Epub Date: 2026-03-19 DOI: 10.23736/S2724-6507.26.04406-4

Meenakshi R Yathindra, Ayush Bhattacharjee, Nikhil Pundir, Pooja Patel, Nidhi E Jacob, Preeti E Jossy, Rajmohan Seetharaman

{"title":"A review of survodutide: a new dual acting agonist.","authors":"Meenakshi R Yathindra, Ayush Bhattacharjee, Nikhil Pundir, Pooja Patel, Nidhi E Jacob, Preeti E Jossy, Rajmohan Seetharaman","doi":"10.23736/S2724-6507.26.04406-4","DOIUrl":"10.23736/S2724-6507.26.04406-4","url":null,"abstract":"Survodutide represents an innovative approach to obesity management and metabolic-associated fatty liver disease (MAFLD). These conditions, often closely linked with type 2 diabetes (T2DM) and cardiovascular diseases, demand effective treatment strategies. Survodutide acts by targeting both GLP-1 and glucagon receptors. This new dual agonist offers potential transformative benefits, with early clinical trials showcasing significant weight loss and improvements in metabolic markers. Survodutide's mechanism of action includes appetite regulation, enhanced glucose metabolism, and increased energy expenditure, making it a promising option for those struggling with obesity and related health issues. This review assesses Survodutide's pharmacology, efficacy, and safety in MASH and obesity, while also outlining its broader metabolic and cardiovascular benefits. It compares Survodutide's dual-agonist mechanism and clinical performance with single-target incretin therapies to clarify its potential role in the evolving treatment landscape. While the initial results are promising, the review emphasizes the importance of continued research to fully understand Survodutide's long-term safety and effectiveness. Ongoing trials will provide critical insights into its overall impact, side effects, patient response, and cost considerations. This article highlights Survodutide's potential in the treatment of obesity and metabolic disordersand evaluates its place in therapy for seeking improved outcomes.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"306-321"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147486776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of oral semaglutide as add-on therapy in poorly controlled type 2 diabetes on background SGLT2 inhibitors: a real-world, multi-center, retrospective, observational study (RYS2). 口服西马鲁肽作为SGLT2抑制剂治疗控制不佳的2型糖尿病的疗效和安全性：一项真实世界、多中心、回顾性、观察性研究（RYS2）

IF 2.3

Minerva endocrinology Pub Date : 2026-09-01 Epub Date: 2025-11-27 DOI: 10.23736/S2724-6507.25.04376-3

Maria E Malighetti, Fabio Vescini, Maria Carpentieri, Anna Altomari, Federica Turchi, Andrea DA Porto, Marco Dauriz

{"title":"Efficacy and safety of oral semaglutide as add-on therapy in poorly controlled type 2 diabetes on background SGLT2 inhibitors: a real-world, multi-center, retrospective, observational study (RYS2).","authors":"Maria E Malighetti, Fabio Vescini, Maria Carpentieri, Anna Altomari, Federica Turchi, Andrea DA Porto, Marco Dauriz","doi":"10.23736/S2724-6507.25.04376-3","DOIUrl":"10.23736/S2724-6507.25.04376-3","url":null,"abstract":"Background: Treatment of type 2 diabetes mellitus (T2DM) relies on diverse glucose-lowering medications, championing sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists as viable options to address concurrent cardiovascular risk. An oral formulation of semaglutide (Rybelsus®, Novo Nordisk) has been recently introduced to clinical use for managing T2DM. Accordingly, there is a paucity of practice evidence while building experience on its combination with SGLT2i.Methods: In this observational, single-arm, retrospective study, data collected from 142 T2DM patients (66% males, 68% older than 60 years, 85% overweight/obese) treated with oral semaglutide in combination with SGLT2i were analyzed.Results: After 6.8±2.6 months of treatment, both glycosylated hemoglobin (HbA1c) and fasting plasma glucose levels significantly improved: 39.6% of patients achieved HbA1c<inf>DCCT</inf> ≤7% (HbA1c<inf>IFCC</inf> ≤53.0 mmol/mol) and 18.8% experienced both a decrease of HbA1c ≥1% and a weight loss ≥5%. In addition, body weight, body mass index, waist circumference, triglycerides, and total cholesterol levels were significantly reduced. Regarding safety, 94.7% of reported adverse events were non-serious gastrointestinal symptoms and 1 patient experienced hypoglycemia.Conclusions: The herein presented real-world data suggest that oral semaglutide can be regarded as safe and effective, when used as add-on medication for uncontrolled T2DM on background SGLT2i.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"248-256"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145636169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genomic mapping of diabetic kidney disease biomarkers and identification of potential inhibitors through virtual screening. 糖尿病肾病生物标志物的基因组定位和通过虚拟筛选鉴定潜在抑制剂。

IF 2.3

Minerva endocrinology Pub Date : 2026-09-01 Epub Date: 2025-10-21 DOI: 10.23736/S2724-6507.25.04399-4

Yi Liu, Yu Wang

{"title":"Genomic mapping of diabetic kidney disease biomarkers and identification of potential inhibitors through virtual screening.","authors":"Yi Liu, Yu Wang","doi":"10.23736/S2724-6507.25.04399-4","DOIUrl":"10.23736/S2724-6507.25.04399-4","url":null,"abstract":"Background: Diabetic kidney disease (DKD) is a common and serious complication of diabetes mellitus, marked by a multifactorial pathogenesis and the absence of sensitive diagnostic biomarkers. Identifying novel molecular targets and therapeutic options is essential to improve early diagnosis and treatment outcomes.Methods: To uncover potential biomarkers and therapeutic candidates, we performed an integrated genomic analysis using microarray and RNA-seq datasets from the Gene Expression Omnibus (GEO) and Sequence Read Archive (SRA) databases. Differentially expressed genes (DEGs) were identified and subjected to protein-protein interaction (PPI) network analysis. Key genes were further explored through virtual screening of an FDA-approved compound library using molecular docking techniques. Drug-likeness was assessed via Lipinski's rule of five.Results: A total of 40 DEGs were identified, among which ISCU (downregulated; involved in iron-sulfur cluster biogenesis) and AP1S2 (upregulated; associated with vesicular trafficking) emerged as potential biomarkers. PPI analysis revealed their involvement in critical DKD-related pathways, such as extracellular matrix remodeling and oxidative stress. Virtual screening identified six FDA-approved compounds with high binding affinity (≤-7.96 kcal/mol) to ISCU, notably ZINC000001576020, all of which complied with Lipinski's rule.Conclusions: This in-silico study nominates ISCU and AP1S2 as candidate diagnostic biomarkers for DKD and identifies computationally prioritized inhibitors targeting ISCU. These findings require experimental validation but provide a molecular framework for precision diagnosis and therapeutic development. These findings offer new molecular insights that could inform precision diagnosis and personalized treatment strategies for diabetic kidney disease.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"266-277"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145337313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Digital platforms influence users and their eating habits. 数字平台影响用户和他们的饮食习惯。

IF 2.3

Minerva endocrinology Pub Date : 2026-09-01 Epub Date: 2026-04-28 DOI: 10.23736/S2724-6507.26.04535-5

Giulia Guarino, Renata Bracale, Martina Ingrosso, Giovanna Muscogiuri, Concetta Vaccaro

引用次数: 0

Obesity-cancer convergence in the destiny of an adipocyte. 肥胖-癌症在脂肪细胞命运中的趋同。

IF 2.3

Minerva endocrinology Pub Date : 2026-09-01 Epub Date: 2026-05-08 DOI: 10.23736/S2724-6507.26.04575-6

Natalia Malara, Antonio Aversa, Francesco Riva

引用次数: 0

Highlights of the July-September 2026 issue. 2026年7月- 9月期的亮点。

IF 2.3

Minerva endocrinology Pub Date : 2026-09-01 DOI: 10.23736/S2724-6507.26.04628-2

Giovanni Vitale

引用次数: 0

Real-time continuous glucose monitoring with subcutaneously inserted sensor correlates better than subcutaneously implantable sensor with glycated hemoglobin, glycated albumin and fructosamine. 与糖化血红蛋白、糖化白蛋白和果糖胺相比，皮下植入传感器实时连续监测血糖的效果更好。

IF 2.3

Minerva endocrinology Pub Date : 2026-09-01 Epub Date: 2026-03-25 DOI: 10.23736/S2724-6507.26.04486-6

Sanja Medenica, Roberto Negro, Djordje Popovic, Michele Chicone, Luigi E Greco

{"title":"Real-time continuous glucose monitoring with subcutaneously inserted sensor correlates better than subcutaneously implantable sensor with glycated hemoglobin, glycated albumin and fructosamine.","authors":"Sanja Medenica, Roberto Negro, Djordje Popovic, Michele Chicone, Luigi E Greco","doi":"10.23736/S2724-6507.26.04486-6","DOIUrl":"10.23736/S2724-6507.26.04486-6","url":null,"abstract":"Background: Real-time continuous glucose monitoring (RT-CGM) is widely used in patients with type 1 diabetes (T1D) to improve glycemic control by reducing postprandial glucose peaks and hypoglycemic episodes. In addition, traditional biomarkers such as glycated hemoglobin (HbA1c), glycated albumin, and fructosamine provide retrospective estimates of glucose regulation over varying timeframes. This study aimed to evaluate the correlation between these biomarkers and glycemic metrics obtained from two types of RT-CGM systems: an implantable sensor (Eversense E3) and subcutaneously inserted sensors (Dexcom G6 and Guardian 4).Methods: We analyzed data from 35 patients with T1D: 13 used the Eversense E3 system, and 22 used Dexcom G6 or Guardian 4. Mean blood glucose (MBG) and time in range (TIR) were assessed at multiple time points and correlated with HbA1c, glycated albumin, and fructosamine levels.Results: In the Eversense group, no significant correlation was observed between CGM-derived metrics and any of the biomarkers. Conversely, in the Dexcom/Guardian group, MBG and TIR demonstrated significant correlations with all biomarkers, showing large effect sizes for HbA1c and fructosamine, and medium for glycated albumin.Conclusions: These findings suggest that the Dexcom G6 and Guardian 4 systems more reliably reflect established biochemical markers of mid- to long-term glucose control, while Eversense may be less consistent in this regard. This highlights the importance of sensor selection when interpreting CGM data for clinical or research applications in diabetes management.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"278-287"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147513367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Amylin role in glucose homeostasis and β-cell function: a robust justification. 胰淀素在葡萄糖稳态和β细胞功能中的作用：一个强有力的理由。

IF 2.3

Minerva endocrinology Pub Date : 2026-09-01 Epub Date: 2026-03-13 DOI: 10.23736/S2724-6507.26.04508-2

Suad H Almasoudi, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Duaa Eliwa, Gaber E Batiha

{"title":"Amylin role in glucose homeostasis and β-cell function: a robust justification.","authors":"Suad H Almasoudi, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Duaa Eliwa, Gaber E Batiha","doi":"10.23736/S2724-6507.26.04508-2","DOIUrl":"10.23736/S2724-6507.26.04508-2","url":null,"abstract":"Amylin is a peptide hormone co-secreted with insulin from pancreatic β-cells that plays a crucial role in glucose homeostasis. Amylin by inhibiting glucagon secretion, slowing gastric emptying, and reducing food intake improves blood glucose and insulin sensitivity. However, emerging evidence suggests that amylin may also contribute to β-cell dysfunction and the development of insulin resistance (IR) in type 2 diabetes (T2D). This review explores the dual roles of amylin in T2D pathogenesis and management, highlighting its therapeutic and pathogenic implications. High amylin levels are associated with amyloid fibril formation, β-cell cytotoxicity, and progression of T2D complications. Conversely, amylin analogues have been shown to improve glycemic control, promote weight loss, and enhance energy balance via dual activation of amylin and calcitonin receptors in the hypothalamus. Experimental and clinical data demonstrate that both detrimental and protective effects of amylin are depending on concentration, duration, and receptor interaction. Amylin and its analogues exhibit paradoxical actions in T2D, acting as both pathogenic and protective effects. While preclinical and limited clinical studies support their role in improving metabolic control, concerns about amyloidogenic toxicity persist. Therefore, further robust clinical trials are needed to clarify amylin's long-term safety and optimize its therapeutic potential in T2D management.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"322-336"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147444294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of hypoglycemic agents on glycemic control and cognitive decline in older adults with type 2 diabetes: real-world evidence on glucagon like peptide 1 receptor agonists. 降糖药对老年2型糖尿病患者血糖控制和认知能力下降的影响：胰高血糖素样肽1受体激动剂的真实证据

IF 2.3

Minerva endocrinology Pub Date : 2026-09-01 Epub Date: 2026-04-02 DOI: 10.23736/S2724-6507.26.04501-X

Benedetta DI Marzio, Giulia Gasparini, Andrea Ambrosio, Alessandra Coin, Luca Filipponi, Giovanni Sartore, Elisabetta Ferra, Mario V Papa, Adele Ravelli, Chiara Ceolin, Marina DE Rui, Bruno M Zanforlini, Chiara Curreri, Anna Bertocco, Maria Devita, Giuseppe Sergi

{"title":"Impact of hypoglycemic agents on glycemic control and cognitive decline in older adults with type 2 diabetes: real-world evidence on glucagon like peptide 1 receptor agonists.","authors":"Benedetta DI Marzio, Giulia Gasparini, Andrea Ambrosio, Alessandra Coin, Luca Filipponi, Giovanni Sartore, Elisabetta Ferra, Mario V Papa, Adele Ravelli, Chiara Ceolin, Marina DE Rui, Bruno M Zanforlini, Chiara Curreri, Anna Bertocco, Maria Devita, Giuseppe Sergi","doi":"10.23736/S2724-6507.26.04501-X","DOIUrl":"10.23736/S2724-6507.26.04501-X","url":null,"abstract":"Background: Type 2 diabetes mellitus (T2DM) is frequently associated with cognitive decline in the older population. Although optimal glycemic control is known to be essential for disease management, the impact of hypoglycemic agents on cognitive function remains poorly investigated.Methods: This retrospective study included 93 geriatric outpatients with T2DM. Hypoglycemic treatments consisted of metformin, sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors, and insulin. Patient evaluations included glycated hemoglobin (HbA1c) measurements, Standardized Mini-Mental State Examination (MMSE), and Mini Nutritional Assessment (MNA).Results: After one year of treatment, patients exhibited a significant reduction in HbA1c levels (from 8.06% [±1.19] to 7.19% [±0.84], P<0.001), improvement of MMSE scores (from 25.87 [±3.09] to 27.47 [±2.9], P<0.001). Regression analysis identified GLP-1RAs as the most effective agent in improving glycemic control (P<0.001) and cognitive function (P=0.016). Treatment with GLP-1RAs was associated with a reduction in MNA scores (P<0.001), though these remained above the malnutrition threshold.Conclusions: Our findings suggest that improved glycemic control may help slow cognitive decline in older patients with T2DM. Among the drug classes examined, GLP-1RAs showed the largest reductions in HbA1c and were linked to greater MMSE score gains.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"257-265"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0